Gainers
InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's drug candidate following proof-of-concept study data.
Wells Fargo analyst Timur Braziler has assumed coverage of 15 banks in addition to the seven currently covered. The analyst transferred coverage of midcap banks, downgraded 4 to Equal Weight, and became more selective given the risk to earnings (rates, credit) and delayed consolidation benefits, mitigated by inexpensive valuations.